4C LABS

4C LABS is a rapidly scaling healthcare, technology, and pharmaceutical start-up focused on virtual prescribing, pharmaceutical distribution, and clinical development in cannabis-based medicinal products for human health. The empirical evidence for the efficacy of CBPM's as a therapeutic agent in the treatment of cancer-related pain, anxiety, childhood epilepsy, spasticity, and sleep disorders is now overwhelming. The company is founded in 2018 and is committed to advancing scientific research, as well as enabling the regulation, distribution, and prescribing of CBPM's in the UK and Channel Islands. Their work with leading scientists, specialist physicians, and pharmacists is underpinned with disruptive technologies that prioritize patients and evidence over stigma. They work closely with Drug Science, the Cannabis Industry Council, The Home Office, The Medicines and Healthcare Regulatory Authority, and the Care Quality Commission to catalyze safe, regulated change in the medical landscape. 4C LABS is open to collaboration with technologists, physicians, scientists, distributors, LPs, or patients and can be contacted at [email protected]. This Pharmaceutical startup, headquartered in the United Kingdom, is poised to make significant strides in the healthcare and pharmaceutical industry. As of now, no public information is available about their last investment or investors.